Clinical Trial Update: Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes safety, tolerability, and efficacy data for valoctocogene roxaparvovec in Hemophilia A patients with inhibitors, evaluated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Roctavian (valoctocogene roxaparvovec)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Hemophilia A With Inhibitor, Hemophilia A With Anti Factor VIII | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING